Physician profile
Mark A Feldner
NPI 1952300873
$2,187.77
in general payments reported to CMS, 2019-2025
29 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $261 · 2021: $244 · 2022: $158 · 2024: $94.07 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $392.78 | 2019-2025 | Ozempic, Wegovy |
| Abbvie INC. | $188.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $185.43 | 2019-2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $184.11 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $139.65 | 2019 | |
| Ethicon INC. | $118.15 | 2022 | |
| Pfizer INC. | $97.90 | 2019-2020 | |
| Exact Sciences Corporation | $97.62 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biotronik INC. | $97.04 | 2019 | |
| Allergan, INC. | $93.20 | 2019-2020 | |
| Glaxosmithkline, LLC. | $77.54 | 2019-2025 | Arexvy, Shingrix |
| Ethicon US, LLC | $54.70 | 2019 | |
| Amarin Pharma, INC. | $48.89 | 2019-2021 | |
| Amgen INC. | $48.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.85 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $37.37 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $35.56 | 2019 | |
| Genentech USA, INC. | $31.75 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.24 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $26.94 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.27 | 2019-2020 | |
| Edwards Lifesciences Corporation | $21.49 | 2022 | |
| Shire North American Group INC | $18.62 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.56 | 2024 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $17.53 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.64 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $14.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Feldner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.